Taken together, we propose that the MYCN-TBX2 CRC represents an important novel therapeutic vulnerability for high-risk NB, warranting future clinical trials to assess available BET and CDK7 inhibitors. This evidence concerns the gene CDK7 and colorectal carcinoma.